Navigation Links
Regado Biosciences Permanently Halts REGULATE-PCI Clinical Trial
Date:8/25/2014

BASKING RIDGE, N.J., Aug. 25, 2014 /PRNewswire/ -- Regado Biosciences, Inc.  today announced the permanent termination of enrollment in its REGULATE-PCI phase 3 trial for its lead program, Revolixys™ Kit. The decision was made based on a recommendation from the trial's Data and Safety Monitoring Board (DSMB) following their analysis of the data from the first approximately 3250 patients enrolled in what was intended to be a 13,200-patient trial comparing the safety and efficacy of Revolixys Kit with bivalirudin.

"The DSMB indicated that the level of serious allergic adverse events associated with Revolixys was of a frequency and severity such that they recommended that we do not enroll any further patients in the REGULATE-PCI trial," stated David J. Mazzo, Ph.D., CEO of Regado. He continued, "We will now undertake a complete review of the unblinded database from REGULATE-PCI, which we expect will take several months to complete."

The Company will hold a conference call and live audio webcast today, Monday, Aug. 25, 2014, at 9:00 a.m. EDT to discuss the termination of its REGULATE-PCI trial.

Interested participants and investors may access the conference call by dialing 1-866-652-5200 for domestic callers or 1-412-317-6060 for international callers. The conference call will be webcast live under the investor relations section of the Regado website at www.regadobio.com and will be archived there for 60 days following the call.

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, Revolixys™ Kit, is a two-component system consisting of pegniva
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights
2. Attention Regado Biosciences, Inc. Investors: Regado Misled Investors According to a Recently Filed Class Action
3. Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board
4. Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
5. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
6. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
7. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
8. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
9. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
10. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
11. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Md. , Sept. 30, 2014  Tasly ... way to modernize medicine, announced today the launch ... of nutraceuticals developed to address men and women ... healthy and vibrant into old age while helping ... includes three condition-specific, whole-food and herb-based formulas, namely, ...
(Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... March 15, 2012  Continuing to meet the complex ... a US-based, ISO13485-certified, FDA compliant contract manufacturing and ... with FDA compliant storage and order fulfillment services ... Telcare,s FDA and HIPAA-compliant solution, ...
... 15, 2012 /PRNewswire-Asia-FirstCall/ --  Dehaier Medical Systems Ltd. ... emerging leader in the development, assembly, marketing and ... today announced that the Company plans to release ... full year of 2011 ended December 31, 2011 on Monday, March ...
Cached Medicine Technology:Cogmedix Provides Medical Device Storage and Order Fulfillment Services for Telcare Medical Supply 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 3
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post ... , Senior citizens can qualify for affordable term ... seniors who are over 50 years old. Some term ... medical examination. , Term life insurance with a simplified ... qualify. Having life insurance during retirement is important for ...
(Date:10/1/2014)... 01, 2014 First Warning Systems, a ... cellular changes throughout the body, announced the company is ... address the company’s breadth of upcoming product releases. The ... screening technology. , “Our initial focus will be an ... detects abnormal circadian cellular changes over time,” said Rob ...
(Date:10/1/2014)... from Duke Medicine suggests that some people who are ... hard-wired to gain weight when exposed to chronic stress, ... 13 percent of people, all of whom are Caucasian, ... help them reduce heart disease with simple interventions such ... "Genetic susceptibility, psychosocial stress and metabolic factors act in ...
(Date:10/1/2014)... Inc., announced today their new NoteSwift™ 2.0 for Allscripts ... the bridge between the EHR and Dragon Medical interpreting ... at the point of care. NoteSwift reduces the time ... than half – and virtually eliminates mouse clicks – ... EHR use according to the June 12, 2014 HIMSS ...
(Date:10/1/2014)... Watsonville, California (PRWEB) October 01, 2014 ... initiative to benefit a very special cause. The ... and support for Paws for Veterans, a nonprofit ... veterans, while also rescuing shelter dogs that would ... purchases of featured products will support monthly donations ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... Residents forced to,leave their homes and businesses due to flooding ... their belongings. The Restoration Industry,Association (RIA, formerly ASCR) suggests that ... during an evacuation:, -- Health & homeowners ... irreplaceable mementos, disposable camera, digital ...
... /PRNewswire/ - Media representatives are invited,to a photo opportunity ... Schwarzenegger, the California Governor, in light of an,international collaboration ... BIO 2008 International Convention in San Diego., ... Health ...
... 18, 2008) -- Could injecting a gene into a ... life-threatening condition? Physician-scientists are setting out to answer that ... to treat severe heart failure. , NewYork-Presbyterian Hospital/Columbia ... New York City area where the therapy is currently ...
... More Components to Fully Measure Quality, WASHINGTON, ... today commended the Centers for Medicare & Medicaid,Services ... care through,the newly introduced "five-star" rating system, but ... index, any system that relies heavily,on survey data ...
... Diagnostic Technologies in Development for Use in ... ... & Johnson Nordic,AB, a Johnson & Johnson company, today announced ... vitro diagnostic (IVD) technologies,for use in Point-of-Care (POC) and near-patient ...
... Thousands of Racers and Sponsorship of Survivor Cafe Continues Longstanding ... Community Support By Binson,s, DETROIT, ... the May 31st Susan G. Komen Detroit Race for,the Cure(R) with the ... team., For 26 years, the Komen Race for the Cure Series ...
Cached Medicine News:Health News:Restoration Industry Association Provides Evacuation Checklist for Residents Impacted by Flooding 2Health News:First gene therapy for heart failure offered at NewYork-Presbyterian/Columbia 2Health News:AHCA Emphasizes Quality Improvement in America's Nursing Homes 2Health News:Johnson & Johnson Nordic AB Acquires Amic 2Health News:Johnson & Johnson Nordic AB Acquires Amic 3Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 2Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 3Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 4
... is a widely used screening test for ... precision oriented Dispette branded system is considered ... tube stamp. No other system meets defined ... patient care. Specialized systems are also available ...
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
... contains 266 amino acids and is variably N-glycosylated. ... estimates of between 43 and 56 kDa. Insulin-like ... with high affinity but do not bind insulin. ... characterized at this time, IGFBP-3 has been shown ...
... the detection and semi-quantitation ... Scl-70 antigen in serum ... the diagnosis of autoimmune ... be performed either manually ...
Medicine Products: